News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AB Science (AB.PA) Announces Recruitment of First Patient in Phase 3 Study of Masitinib in Progressive Multiple Sclerosis


9/6/2011 10:45:03 AM

PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (NYSE-Euronext, FR0010557264, AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today recruitment of the first patient in the phase 3 study of masitinib in primary progressive multiple sclerosis or relapse free secondary progressive multiple sclerosis.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES